Date: 2017-04-04
Type of
information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the American Association for Cancer Research (AACR) Annual Meeting
Company: VBL Therapeutics (Israel)
Product: VB-600 series
Action
mechanism:
Disease:
Therapeutic
area: Cancer - Oncology
Country:
Trial
details:
Latest
news:
- • On April 4, 2017, VBL Therapeutics announce the presentation of new data on MOSPD2, a novel potential target in oncology. VBL's study, entitled "MOSPD2, a Newly Characterized Protein, Promotes Breast Cancer Metastasis" by Mendel et al., have been presented at the American Association of Cancer research (AACR) conference. The study observed from clinical biopsies that MOSPD2 is prevalent in invasive human breast cancer tissue and that levels of MOSPD2 correlate to breast cancer invasiveness. It was further observed that a knockdown of MOSPD2 in a human breast cancer cell line using CRISPR technology led to blockade of EGF signaling and significant reduction of breast cancer cell migration in vitro and metastasis in a mouse model. VBL believes that targeting of MOSPD2 may have several therapeutic applications, including inhibition of tumor cell metastases and targeting of MOSPD2-positive tumor cells, as well as inhibition of monocyte migration in chronic inflammatory conditions. VBL's "VB-600 series" of pipeline candidates is being developed towards these applications.
• On January 31, 2017, VBL Therapeutics announced the publication of a paper discussing MOSPD2, a potential novel immuno-oncology target. The paper, entitled, "Identification of Motile Sperm Domain–Containing Protein 2 as Regulator of Human Monocyte Migration" by Mendel et al., is published online in The Journal of Immunology. VBL's manuscript reveals that MOSPD2, a protein with a previously unknown function, regulates cell migration in human monocytes. While this first manuscript focuses on the importance of MOSPD2 in immune cells, research conducted by VBL has explored the relevance of MOSPD2 in motility and metastasis of tumor cells.
- This novel platform technology enriches VBL's capabilities, which include the Vascular Targeting System (VTS™) gene-therapy-based platform technology lead by the Phase 3 drug candidate VB-111 (ofranergene obadenovec) and the Lecinoxoids family of small molecules which have potential applications in cardiovascular, NASH and fibrotic diseases. The company believes that targeting of MOSPD2 may have several therapeutic applications, including inhibition of monocyte migration in chronic inflammatory conditions, inhibition of tumor cell metastases and targeting of MOSPD2+ tumor cells. VBL's "VB-600 series" of pipeline candidates is being developed towards these applications. The company expects to report additional findings related to MOSPD2 in Q2 2017.
Is
general: Yes
